Kasper Grosen1, Asbjørn Mohr Drewes2, Anette Højsgaard3, Mogens Pfeiffer-Jensen4, Vibeke Elisabeth Hjortdal3, Hans Kristian Pilegaard3. 1. Department of Cardiothoracic and Vascular Surgery, Aarhus University Hospital, Aarhus, Denmark kasper.grosen@ki.au.dk. 2. Mech-Sense, Department of Gastroenterology and Hepatology, Aalborg University Hospital, Aalborg, Denmark Center for Sensory-Motor Interaction, Department of Health Science and Technology, Aalborg University, Aalborg, Denmark. 3. Department of Cardiothoracic and Vascular Surgery, Aarhus University Hospital, Aarhus, Denmark. 4. Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark.
Abstract
OBJECTIVES: To evaluate the effect of perioperative gabapentin treatment for the prevention of persistent post-thoracotomy pain and to establish whether gabapentin has a significant therapeutic impact on acute postoperative pain. METHODS:Consecutive patients with pulmonary malignancies scheduled for anterior thoracotomy were enrolled in this randomized, double-blinded, placebo-controlled trial. Patients were given 1200 mg gabapentin or placebo 2 h before surgery followed by increasing doses during 5 postoperative days: 600 mg for day 1; 900 mg for day 2; and 1200 mg for days 3-5. Effective pain relief was provided with perioperative multimodal analgesia with epidural infusion of bupivacaine and morphine for 72 h, and oral acetaminophen, ibuprofen and morphine. The main outcome was persistent post-thoracotomy pain at 6 months. Secondary outcomes included measures of early postoperative post-thoracotomy pain, morphine requirements, recovery and analgesia-related adverse effects over the first 3 weeks as well as persistent post-thoracotomy pain at 3 months. RESULTS: A total of 104 patients were randomly assigned to the intervention or control group; 86 (83%) patients were available for the 14-day analysis, 76 (73%) for the 3-month analysis and 67 (64%) for the 6-month follow-up. At 6 months postoperatively, 47% of patients treated with gabapentin reported persistent post-thoracotomy pain compared with 49% in the placebo group (P = 0.9). No overall clinically or statistically significant differences were observed between groups receiving placebo and gabapentin, respectively, for the secondary outcome measures and treatment-related adverse events. CONCLUSIONS: We found no evidence for the superiority of gabapentin over placebo for the treatment of acute pain following thoracotomy or for the prevention of persistent post-thoracotomy pain.
RCT Entities:
OBJECTIVES: To evaluate the effect of perioperative gabapentin treatment for the prevention of persistent post-thoracotomy pain and to establish whether gabapentin has a significant therapeutic impact on acute postoperative pain. METHODS: Consecutive patients with pulmonary malignancies scheduled for anterior thoracotomy were enrolled in this randomized, double-blinded, placebo-controlled trial. Patients were given 1200 mg gabapentin or placebo 2 h before surgery followed by increasing doses during 5 postoperative days: 600 mg for day 1; 900 mg for day 2; and 1200 mg for days 3-5. Effective pain relief was provided with perioperative multimodal analgesia with epidural infusion of bupivacaine and morphine for 72 h, and oral acetaminophen, ibuprofen and morphine. The main outcome was persistent post-thoracotomy pain at 6 months. Secondary outcomes included measures of early postoperative post-thoracotomy pain, morphine requirements, recovery and analgesia-related adverse effects over the first 3 weeks as well as persistent post-thoracotomy pain at 3 months. RESULTS: A total of 104 patients were randomly assigned to the intervention or control group; 86 (83%) patients were available for the 14-day analysis, 76 (73%) for the 3-month analysis and 67 (64%) for the 6-month follow-up. At 6 months postoperatively, 47% of patients treated with gabapentin reported persistent post-thoracotomy pain compared with 49% in the placebo group (P = 0.9). No overall clinically or statistically significant differences were observed between groups receiving placebo and gabapentin, respectively, for the secondary outcome measures and treatment-related adverse events. CONCLUSIONS: We found no evidence for the superiority of gabapentin over placebo for the treatment of acute pain following thoracotomy or for the prevention of persistent post-thoracotomy pain.
Authors: Jennifer S Gewandter; Robert H Dworkin; Dennis C Turk; John T Farrar; Roger B Fillingim; Ian Gilron; John D Markman; Anne Louise Oaklander; Michael J Polydefkis; Srinivasa N Raja; James P Robinson; Clifford J Woolf; Dan Ziegler; Michael A Ashburn; Laurie B Burke; Penney Cowan; Steven Z George; Veeraindar Goli; Ole X Graff; Smriti Iyengar; Gary W Jay; Joel Katz; Henrik Kehlet; Rachel A Kitt; Ernest A Kopecky; Richard Malamut; Michael P McDermott; Pamela Palmer; Bob A Rappaport; Christine Rauschkolb; Ilona Steigerwald; Jeffrey Tobias; Gary A Walco Journal: Pain Date: 2015-07 Impact factor: 7.926
Authors: Jennifer Hah; Sean C Mackey; Peter Schmidt; Rebecca McCue; Keith Humphreys; Jodie Trafton; Bradley Efron; Debra Clay; Yasamin Sharifzadeh; Gabriela Ruchelli; Stuart Goodman; James Huddleston; William J Maloney; Frederick M Dirbas; Joseph Shrager; John G Costouros; Catherine Curtin; Ian Carroll Journal: JAMA Surg Date: 2018-04-01 Impact factor: 16.681
Authors: Kathleen G Hopkins; Leslie A Hoffman; Annette De Vito Dabbs; Peter F Ferson; Linda King; Linda A Dudjak; Thomas G Zullo; Margaret Q Rosenzweig Journal: J Adv Pract Oncol Date: 2015-03-01